Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Endocrinol (Lausanne). 2021 Jul 15;12:692082. doi: 10.3389/fendo.2021.692082. eCollection 2021.
Calcium is a crucial factor in regulating the biological behavior of cells. The imbalance of calcium homeostasis in cytoplasm will cause abnormal behavior of cells and the occurrence of diseases. In intracytoplasmic sperm injection (ICSI) cycle, the dysfunction of oocyte activation caused by insufficient release of Ca from endoplasmic reticulum is one of the main reasons for repeated fertilization failure. Calcium ionophore (A23187) is a highly selective calcium ionophore, which can form stable complex with Ca and pass through the cell membrane at will, effectively increasing intracellular Ca levels. It has been reported that calcium ionophore (A23187) can activate oocytes and obtain normal embryos. However, there are few studies on unfertilized oocytes after calcium ionophore (A23187) rescue activation in ICSI cycle. The purpose of this study was to analyze the effects of calcium ionophore (A23187) rescue activation on the activation of unfertilized oocytes, embryonic development potential, embryonic development timing and chromosomal aneuploidy, and to compare and analyze the clinical data of patients with calcium ionophore (A23187) activation in clinical application. The results showed that a certain proportion of high-quality blastocysts with normal karyotype could be obtained after calcium ionophore (A23187) rescue activation of unfertilized oocytes, and it did not have a significant effect on the timing of embryo development. In clinical practice, direct activation with calcium ionophore (A23187) after ICSI was better than rescue activation the next day. In conclusions, the studies on the effectiveness and safety of calcium ionophore (A23187) rescue activation for oocytes with ICSI fertilization failure can enable some patients to obtain usable, high-quality embryos during the first ICSI cycle.
钙是调节细胞生物行为的关键因素。细胞质中钙稳态失衡会导致细胞异常行为和疾病的发生。在卵胞浆内单精子注射(ICSI)周期中,由于内质网钙离子释放不足导致的卵母细胞激活功能障碍是反复受精失败的主要原因之一。钙离子载体(A23187)是一种高度选择性的钙离子载体,可与 Ca 形成稳定的复合物,并随意穿过细胞膜,有效增加细胞内 Ca 水平。有报道称,钙离子载体(A23187)可激活卵母细胞并获得正常胚胎。然而,对于 ICSI 周期中钙离子载体(A23187)拯救激活后的未受精卵母细胞,研究较少。本研究旨在分析钙离子载体(A23187)拯救激活对未受精卵母细胞激活、胚胎发育潜能、胚胎发育时机和染色体非整倍性的影响,并对钙离子载体(A23187)在临床应用中的激活患者的临床数据进行比较和分析。结果表明,通过钙离子载体(A23187)拯救激活未受精卵母细胞,可以获得一定比例的具有正常核型的高质量囊胚,且对胚胎发育时机无显著影响。在临床实践中,ICSI 后直接用钙离子载体(A23187)激活优于次日的挽救激活。总之,关于钙离子载体(A23187)对 ICSI 受精失败卵母细胞的有效性和安全性的研究,可以使一些患者在第一次 ICSI 周期中获得可用的、高质量的胚胎。